The Nucleic Acid-based Therapeutics Market size was valued at USD 5.36 billion in 2023 and is expected to grow to USD 14.25 billion by 2031 and grow at a CAGR of 13.5% over the forecast period of 2024-2031.
Nucleic Acid-based Therapeutics are the nucleic acid themselves or closely related compounds of nucleic acid used to treat disease. Various types of Therapeutic Nucleic Acids (TNA) are present but all the types share a common mechanism of action that is mediated by sequence‐specific recognition of endogenous nucleic acids through Watson–Crick base pairing. Specificity is one of the greatest benefits of nucleic acid-based medicines.
Get more information on Nucleic Acid-based Therapeutics Market - Request Sample Report
Nucleic acid therapeutics have the potential to treat diseases by targeting their genetic blueprint in vivo. Nucleic acid therapeutics are able to achieve a long-lasting, curative effect via gene inhibition, replacement, addition, or editing by using synthetic oligonucleotides. In contrast, conventional treatment target proteins rather than underlying causes as they induce therapeutic effects that are transient. The clinical translation of nucleic acid-based therapeutics is depend upon the delivery technology which increases the target affinity, improves stability, and facilitates internalization.
Because of their susceptibility to nuclease destruction, difficulty in delivery to a cell, and contribution to immune response, nucleic acids present a challenge for therapeutic uses. Improved technology for the stability, internalization, and target affinity of the synthesized oligonucleotides is necessary for the clinical success of nucleic acid treatments.
Nowadays RNA-based therapeutics are more in view than DNA-based therapeutics because DNA is not directly linked to proteins. Between the genetic material and the protein, RNA is a crucial intermediary step. For the creation of "next-generation" biotherapeutics, RNA-related technology is currently the main area of interest.
Drivers
Shifting focus of the pharmaceutical market toward innovative biologic and cell and gene therapy products
Rising approvals of nucleic acid therapeutics
Unpredictable increase in the cases of COVID-19 patient
Rapidly growing prevalence of chronic diseases such as cardiovascular diseases and cancer.
Rising investment in nucleic acid-based therapeutics
Restrain
High cost associated with the nucleic acid-based therapeutics
Opportunities
The high number of under-clinical trial drugs which are waiting to be approved for the prevention of various diseases.
Challenges
Mass production and targeted delivery at low cost
The COVID-19 pandemic has had a profound impact on the world, causing significant changes to our daily lives and highlighting the limitations of our current therapeutic options in the fight against this deadly virus. However, this crisis has also brought attention to the potential of RNA molecules as therapeutic agents, particularly nucleic acid-based drugs with anti-viral properties.
These drugs have shown promise in arresting the progression of viral diseases, thanks to their versatile mode of action and ability to suppress viral replication and gene expression. Additionally, they have the potential to produce a wide range of anti-viral immunity in the body, making them particularly effective in the treatment of SARS-CoV-2.
As a result, the market for nucleic acid-based therapeutics has experienced significant growth during the pandemic. This is an exciting development that could lead to new and more effective treatments for a range of viral diseases, including COVID-19.
The current economic recession has had a significant impact on various industries, including the nucleic acid-based therapeutics market. This market involves the development and commercialization of drugs that target genetic material, such as DNA and RNA, to treat various diseases. The recession has led to a decrease in funding for research and development in this field, as well as a decrease in investment in companies that specialize in nucleic acid-based therapeutics. This has resulted in a slowdown in the development of new drugs and a decrease in the number of clinical trials being conducted.
Furthermore, the recession has also affected the demand for these drugs. Patients are less likely to seek out expensive treatments, and healthcare providers are less likely to prescribe them due to cost concerns. This has led to a decrease in sales and revenue for companies in this market.
By Technology:
RNA-targeted therapeutics
Gene therapies
Epigenetic and microRNA modulating therapies
Genome editing therapies
Others
By End-user:
Hospitals & Clinics
Academic & Research Institutes
Others
By Application:
Autoimmune Disorders
Infectious Diseases
Genetic Disorders
Cancer
Others
Get Customized Report as per your Business Requirement - Request For Customized Report
By region, North America dominated the market with the largest market share and is forecasted to grow with the highest CAGR in the future. This is owing to increasing approvals of novel nucleic acid treatments and the availability of nucleic acid extraction technology. Due to the availability of all favorable factors, the market growth of this region is at its peak and is expected to remain the same during the forecast period. The increasing investments in R&D activities in the United States are estimated to show a major impact on regional market growth during the forecast period.
Europe’s Nucleic acid-based therapeutic market is the second-largest market owing to the rising investment in the diagnostic and research sectors. The growth in this region is also attributed to the increasing prevalence of infectious diseases.
REGIONAL COVERAGE:
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Rest of Europe
Asia-Pacific
Japan
south Korea
China
India
Australia
Rest of Asia-Pacific
The Middle East & Africa
Israel
UAE
South Africa
Rest of the Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
The market for nucleic acid-based therapeutics is experiencing a surge in innovation, resulting in a growing number of companies entering the market. The success of mRNA vaccines in combating the COVID-19 pandemic has catapulted Moderna and BioNTech to the forefront of the industry, leading to exponential revenue growth in 2019. While established companies continue to innovate in the therapeutic space, small biotech ventures are also making significant contributions. These ventures are introducing breakthrough methodologies such as circular RNA, transfer RNA (tRNA), and self-replicating RNA.
Alltrna and Shape Therapeutics are among the companies developing therapeutics based on tRNA molecules that can correct genetic code errors that would otherwise impair protein production. Meanwhile, Laronde and Orna Therapeutics are working on circular RNA.
The emergence of these new methodologies is a promising development for the nucleic acid-based therapeutics market. As more companies enter the space and bring innovative solutions to the table, we can expect to see continued growth and progress in this field.
The Key Players are Silence Therapeutics plc, Ionis Pharmaceuticals, Novartis, Merck, Arrowhead Pharmaceuticals, BioNtech, Pfizer Inc, Protagonist Therapeutics, Inc, Biomedica, Moderna Inc., and Alnylam Pharmaceuticals, Inc. & Other Players.
| Report Attributes | Details |
| Market Size in 2023 | US$ 5.36 Bn |
| Market Size by 2031 | US$ 14.25 Bn |
| CAGR | CAGR of 13.5% From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Technology (RNA targeted therapeutics, Gene therapies, Epigenetic and micro-RNA modulating therapies, Genome editing therapies, and Others) • By End-user (Hospitals & Clinics, Academic & Research Institutes, and Others) • By Application (Autoimmune Disorders, Infectious Diseases, Genetic Disorders, Cancer, and Others) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Silence Therapeutics plc, Ionis Pharmaceuticals, Novartis, Merck, Arrowhead Pharmaceuticals, BioNtech, Pfizer Inc, Protagonist Therapeutics, Inc, Biomedica, Moderna Inc., and Alnylam Pharmaceuticals, Inc. |
| Key Drivers | • Shifting focus of the pharmaceutical market toward innovative biologic and cell and gene therapy products • Rising approvals of nucleic acid therapeutics |
| Market Opportunities | • The high number of under-clinical trial drugs which are waiting to be approved for the prevention of various diseases. |
The expected CAGR of the global Nucleic Acid-based Therapeutics Market during the forecast period is 13.5%.
The forecasted market size of the Nucleic Acid-based Therapeutics Market is expected to reach USD 14.25 billion in 2031.
The major key players are Silence Therapeutics plc, Ionis Pharmaceuticals, Novartis, Merck, Arrowhead Pharmaceuticals, BioNtech, Pfizer Inc, Protagonist Therapeutics, Inc, Biomedica, Moderna Inc., and Alnylam Pharmaceuticals, Inc.
North America region dominated the Nucleic Acid-based Therapeutics Market.
Accelerating Shift of the Pharmaceutical Market Toward Innovative Biologic and Cell and Gene Therapy Products, Rising Approvals of Nucleic Acid Therapeutics, Unpredictable increase in the cases of COVID-19 patients, Increase in the prevalence of chronic diseases such as cardiovascular diseases and cancer, and Rising investment in nucleic acid-based therapeutics are the major driving factors of nucleic acid-based therapeutics market.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Nucleic Acid-based Therapeutics Market Segmentation, By Technology
8.1 RNA-targeted therapeutics
8.2 Gene therapies
8.3 Epigenetic and microRNA modulating therapies
8.4 Genome editing therapies
8.5 Others
9. Nucleic Acid-based Therapeutics Market Segmentation, By End-user
9.1 Hospitals & Clinics
9.2 Academic & Research Institutes
9.3 Others
10. Nucleic Acid-based Therapeutics Market Segmentation, By Application
10.1 Autoimmune Disorders, Cancer
10.2 Infectious Diseases
10.3 Genetic Disorders
10.4 Cancers
10.5 Others
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Nucleic Acid-based Therapeutics Market by Country
11.2.2North America Nucleic Acid-based Therapeutics Market by Technology
11.2.3 North America Nucleic Acid-based Therapeutics Market by End-user
11.2.4 North America Nucleic Acid-based Therapeutics Market by Application
11.2.5 USA
11.2.5.1 USA Nucleic Acid-based Therapeutics Market by Technology
11.2.5.2 USA Nucleic Acid-based Therapeutics Market by End-user
11.2.5.3 USA Nucleic Acid-based Therapeutics Market by Application
11.2.6 Canada
11.2.6.1 Canada Nucleic Acid-based Therapeutics Market by Technology
11.2.6.2 Canada Nucleic Acid-based Therapeutics Market by End-user
11.2.6.3 Canada Nucleic Acid-based Therapeutics Market by Application
11.2.7 Mexico
11.2.7.1 Mexico Nucleic Acid-based Therapeutics Market by Technology
11.2.7.2 Mexico Nucleic Acid-based Therapeutics Market by End-user
11.2.7.3 Mexico Nucleic Acid-based Therapeutics Market by Application
11.3 Europe
11.3.1 Europe Nucleic Acid-based Therapeutics Market by Country
11.3.2 Europe Nucleic Acid-based Therapeutics Market by Technology
11.3.3 Europe Nucleic Acid-based Therapeutics Market by End-user
11.3.4Europe Nucleic Acid-based Therapeutics Market by Application
11.3.5Germany
11.3.5.1 Germany Nucleic Acid-based Therapeutics Market by Technology
11.3.5.2 Germany Nucleic Acid-based Therapeutics Market by End-user
11.3.5.3 Germany Nucleic Acid-based Therapeutics Market by Application
11.3.6 UK
11.3.6.1 UK Nucleic Acid-based Therapeutics Market by Technology
11.3.6.2 UK Nucleic Acid-based Therapeutics Market by End-user
11.3.6.3 UK Nucleic Acid-based Therapeutics Market by Application
11.3.7 France
11.3.7.1 France Nucleic Acid-based Therapeutics Market by Technology
11.3.7.2 France Nucleic Acid-based Therapeutics Market by End-user
11.3.7.3 France Nucleic Acid-based Therapeutics Market by Application
11.3.8 Italy
11.3.8.1 Italy Nucleic Acid-based Therapeutics Market by Technology
11.3.8.2 Italy Nucleic Acid-based Therapeutics Market by End-user
11.3.8.3 Italy Nucleic Acid-based Therapeutics Market by Application
11.3.9 Spain
11.3.9.1 Spain Nucleic Acid-based Therapeutics Market by Technology
11.3.9.2 Spain Nucleic Acid-based Therapeutics Market by End-user
11.3.9.3 Spain Nucleic Acid-based Therapeutics Market by Application
11.3.10 The Netherlands
11.3.10.1 Netherlands Nucleic Acid-based Therapeutics Market by Technology
11.3.10.2 Netherlands Nucleic Acid-based Therapeutics Market by End-user
11.3.10.3 Netherlands Nucleic Acid-based Therapeutics Market by Application
11.3.11 Rest of Europe
11.3.11.1 Rest of Europe Nucleic Acid-based Therapeutics Market by Technology
11.3.11.2 Rest of Europe Nucleic Acid-based Therapeutics Market by End-user
11.3.11.3 Rest of Europe Nucleic Acid-based Therapeutics Market by Application
11.4 Asia-Pacific
11.4.1 Asia Pacific Nucleic Acid-based Therapeutics Market by Country
11.4.2Asia Pacific Nucleic Acid-based Therapeutics Market by Technology
11.4.3 Asia Pacific Nucleic Acid-based Therapeutics Market by End-user
11.4.4 Asia Pacific Nucleic Acid-based Therapeutics Market by Application
11.4.5 Japan
11.4.5.1 Japan Nucleic Acid-based Therapeutics Market by Technology
11.4.5. 2Japan Nucleic Acid-based Therapeutics Market by End-user
11.4.5. 3Japan Nucleic Acid-based Therapeutics Market by Application
11.4.6 South Korea
11.4.6.1 South Korea Nucleic Acid-based Therapeutics Market by Technology
11.4.6.2. South Korea Nucleic Acid-based Therapeutics Market by End-user
11.4.6.3. South Korea Nucleic Acid-based Therapeutics Market by Application
11.4.7China
11.4.7.1 China Nucleic Acid-based Therapeutics Market by Technology
11.4.7.2. China Nucleic Acid-based Therapeutics Market by End-user
11.4.7.3. China Nucleic Acid-based Therapeutics Market by Application
11.4.8 India
11.4.8.1 India Nucleic Acid-based Therapeutics Market by Technology
11.4.8.2. India Nucleic Acid-based Therapeutics Market by End-user
11.4.8.3 India Nucleic Acid-based Therapeutics Market by Application
11.4.9Australia
11.4.9.1 Australia Nucleic Acid-based Therapeutics Market by Technology
11.4.9.2. Australia Nucleic Acid-based Therapeutics Market by End-user
11.4.9.3. Australia Nucleic Acid-based Therapeutics Market by Application
11.4.10Rest of Asia-Pacific
11.4.10.1 APAC Nucleic Acid-based Therapeutics Market by Technology
11.4.10.2. APAC Nucleic Acid-based Therapeutics Market by End-user
11.4.10.3. APAC Nucleic Acid-based Therapeutics Market by Application
11.5 The Middle East & Africa
11.5.1 The Middle East & Africa Nucleic Acid-based Therapeutics Market by Country
11.5.2 The Middle East & Africa Nucleic Acid-based Therapeutics Market by Technology
11.5.3The Middle East & Africa Nucleic Acid-based Therapeutics Market by End-user
11.5.4The Middle East & Africa Nucleic Acid-based Therapeutics Market by Application
11.5.5Israel
11.5.5.1 Israel Nucleic Acid-based Therapeutics Market by Technology
11.5.5.2 Israel Nucleic Acid-based Therapeutics Market by End-user
11.5.5.3 Israel Nucleic Acid-based Therapeutics Market by Application
11.5.6 UAE
11.5.6.1 UAE Nucleic Acid-based Therapeutics Market by Technology
11.5.6.2 Israel Nucleic Acid-based Therapeutics Market by End-user
11.5.6.3 Israel Nucleic Acid-based Therapeutics Market by Application
11.5.7South Africa
11.5.7.1 South Africa Nucleic Acid-based Therapeutics Market by Technology
11.5.7.2 South Africa Nucleic Acid-based Therapeutics Market by End-user
11.5.7.3 South Africa Nucleic Acid-based Therapeutics Market by Application
11.5.8 Rest of Middle East & Africa
11.5.8.1 Rest of Middle East & Asia Nucleic Acid-based Therapeutics Market by Technology
11.5.8.2 Rest of Middle East & Asia Nucleic Acid-based Therapeutics Market by End-user
11.5.8.3 Rest of Middle East & Asia Nucleic Acid-based Therapeutics Market by Application
11.6 Latin America
11.6.1 Latin America Nucleic Acid-based Therapeutics Market by Country
11.6.2. Latin America Nucleic Acid-based Therapeutics Market by Technology
11.6.3 Latin America Nucleic Acid-based Therapeutics Market by End-user
11.6.4 Latin America Nucleic Acid-based Therapeutics Market by Application
11.6.5 Brazil
11.6.5.1 Brazil Nucleic Acid-based Therapeutics Market by Technology
11.6.5.2 Brazil Nucleic Acid-based Therapeutics Market by End-user
11.6.5.3Brazil Nucleic Acid-based Therapeutics Market by Application
11.6.6Argentina
11.6.6.1 Argentina Nucleic Acid-based Therapeutics Market by Technology
11.6.6.2 Argentina Nucleic Acid-based Therapeutics Market by End-user
11.6.6.3 Argentina Nucleic Acid-based Therapeutics Market by Application
11.6.7Rest of Latin America
11.6.7.1 Rest of Latin America Nucleic Acid-based Therapeutics Market by Technology
11.6.7.2 Rest of Latin America Nucleic Acid-based Therapeutics Market by End-user
11.6.7.3Rest of Latin America Nucleic Acid-based Therapeutics Market by Application
12. Company Profile
12.1 Silence Therapeutics plc
12.1.1 Market Overview
12.1.2 Financials
12.1.3 Product/Services/Offerings
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Ionis Pharmaceuticals
12.2.1 Market Overview
12.2.2 Financials
12.2.3 Product/Services/Offerings
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 Novartis
12.3.1 Market Overview
12.3.2 Financials
12.3.3 Product/Services/Offerings
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Merck
12.4.1 Market Overview
12.4.2 Financials
12.4.3 Product/Services/Offerings
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 Arrowhead Pharmaceuticals
12.5.1 Market Overview
12.5.2 Financials
12.5.3 Product/Services/Offerings
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 BioNtech
12.6.1 Market Overview
12.6.2 Financials
12.6.3 Product/Services/Offerings
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 Pfizer Inc
12.7.1 Market Overview
12.7.2 Financials
12.7.3 Product/Services/Offerings
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 Protagonist Therapeutics
12.8.1 Market Overview
12.8.2 Financials
12.8.3 Product/Services/Offerings
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Biomedica
12.9.1 Market Overview
12.9.2 Financials
12.9.3 Product/Services/Offerings
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10 Moderna Inc.
12.10.1 Market Overview
12.10.2 Financials
12.10.3 Product/Services/Offerings
12.10.4 SWOT Analysis
12.10.5 The SNS View
12.11 Alnylam Pharmaceuticals, Inc.
12.11.1 Market Overview
12.11.2 Financials
12.11.3 Product/Services/Offerings
12.11.4 SWOT Analysis
12.11.5 The SNS View
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share analysis
13.3 Recent Developments
14. USE Cases And Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Basalt Fiber Market Size was $278 million out of 2023 and is supposed to arrive at $712.7 million by 2031, and develop at a CAGR of 12.49% by 2024-2031
The Bromine Market Size was valued at USD 3.7 billion in 2023 and is expected to reach USD 5.4 billion by 2032 and grow at a CAGR of 4.2% over the forecast period 2024-2032.
Explore the Caprylic Acid Market, focusing on key applications in food, pharmaceuticals, and personal care. Learn about trends in the demand for natural antimicrobial agents, MCT supplements, and how caprylic acid is used in various industries for its hea
The Fructooligosaccharides Market Size was valued at USD 2.6 billion in 2023, and is expected to reach USD 5.5 billion by 2032, and grow at a CAGR of 8.7% over the forecast period 2024-2032.
The Polyethylene Glycol Market Size was valued at USD 5.0 billion in 2023, and is expected to reach USD 8.4 billion by 2032, and grow at a CAGR of 6.0% over the forecast period 2024-2032.
The Geofoam Market Size was valued at USD 764.9 million in 2023 and is expected to reach USD 1466.60 million by 2032 and grow at a CAGR of 7.50% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
